It has been three months since the U.S. Supreme Court’s decision in Prometheus and, with the recent grant-vacate-remand of Ultramercial to the Federal Circuit, the patent bar is left to speculate on the application of this holding both within and outside of medical diagnostics.
This article investigates the court’s conflation of the novelty inquiry under 35 USC § 102 with the patent-eligibility inquiry under § 101. We conclude that the court’s desire to avoid rendering as a dead letter the "law of nature" exception to § 101 patentability has, apparently unwittingly, rendered § 102 a dead letter for certain types of claims. Left open and unresolved is the question of whether the expanded scope of § 101 also implicates the inquiry for obviousness under § 103.
Click here to read the entire article as published by Law360.